Evidence map›Paper›PMID 27292583›Full record

ArticleBritish journal of haematology2017

Heavy/light chain ratio normalization prior to transplant is of independent prognostic significance in multiple myeloma: a BMT CTN 0102 correlative study.

Anita D'Souza, Marcelo Pasquini, Brent Logan, Sergio Giralt, Amrita Krishnan, Joseph Antin, Alan Howard, Stacy Goodman, Muzzafar Qazilbash, Kristin Knust and 6 more

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of haematology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Anita D'SouzaMedical College of Wisconsin, Milwaukee, WI, USA.
Marcelo PasquiniMedical College of Wisconsin, Milwaukee, WI, USA.
Brent LoganMedical College of Wisconsin, Milwaukee, WI, USA.
Sergio GiraltMemorial Sloan-Kettering Cancer Center, New York, NY, USA.
Amrita KrishnanCity of Hope Cancer Center, Los Angeles, CA, USA.
Joseph AntinDana-Farber Cancer Institute, Boston, MA, USA.
Alan HowardNational Marrow Donor Program, Minneapolis, MN, USA.
Stacy GoodmanVanderbilt University Medical Center and Veterans Affairs Tennessee Valley Healthcare System, Nashville, TN, USA.
Muzzafar QazilbashMD Anderson Cancer Research Center, Houston, TX, USA.
Kristin KnustThe EMMES Corporation, Rockville, MD, USA.
Firoozeh SahebiCity of Hope Cancer Center, Los Angeles, CA, USA.
Daniel WeisdorfUniversity of Minnesota, Minneapolis, MN, USA.
David VesoleHackensack University Medical Center, Hackensack, NJ, USA.
Edward StadtmauerUniversity of Pennsylvania Abramson Cancer Center, Philadelphia, PA, USA.
David MaloneyFred Hutchison Cancer Center, Seattle, WA, USA.
Parameswaran HariMedical College of Wisconsin, Milwaukee, WI, USA.

Funding

Data Resource for Analyzing Blood &Marrow TransplantsU24CA076518 · NCI · MEDICAL COLLEGE OF WISCONSIN · PI Amy M Moskop, Bronwen Shaw · 1998 to 2026
$105.2M
Easy-to-read Informed Consent for HCT Clinical TrialsU10HL069294 · NHLBI · MEDICAL COLLEGE OF WISCONSIN · PI HOROWITZ, MARY MARESCA · 2011 to 2016
$43.8M
City of Hope Core Clinical Center for the Blood and Marrow Transplant Clinical Trials NetworkUG1HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI RYOTARO NAKAMURA · 2017 to 2026
$2.2M
MSKCC BMT CTN RenewalUG1HL069315 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI MIGUEL-ANGEL PERALES · 2017 to 2026
$2.2M
BMT CTN Core - Dana-Farber Cancer Institute and MGH ConsortiumUG1HL069249 · NHLBI · DANA-FARBER CANCER INST · PI Mahasweta Gooptu · 2017 to 2026
$2.2M
BMT CTN Core- University of Pennsylvania Abramson Cancer CenterUG1HL069286 · NHLBI · UNIVERSITY OF PENNSYLVANIA · PI Edward A Stadtmauer · 2017 to 2026
$2.0M
MSKCC BMT CTN Renewal U10HL069315 · NHLBI · SLOAN-KETTERING INST CAN RESEARCH · PI GIRALT, SERGIO A · 2011 to 2016
$1.1M
A Randomized Trial of Tac/MTX/bortezomib vs Tac/MTXplacebo in Allogeneic HSCTU10HL069249 · NHLBI · DANA-FARBER CANCER INST · PI ANTIN, JOSEPH H · 2011 to 2016
$1.1M
Blood and Marrow Transplant Clinical Research NetworkU10HL069278 · NHLBI · BECKMAN RESEARCH INSTITUTE/CITY OF HOPE · PI NAKAMURA, RYOTARO · 2011 to 2016
$1.0M
Sargrastim and Plerixafor vs. Filgrastim for Allogeneic Stem Cell MobilizationU10HL109137 · NHLBI · WASHINGTON UNIVERSITY · PI WESTERVELT, PETER · 2011 to 2016
$937k
Enhancing the Safety of Allogeneic TransplantationU10HL069290 · NHLBI · UNIVERSITY OF MINNESOTA · PI WEISDORF, DANIEL J · 2011 to 2016
$931k
NCI NIH HHS U24 CA076518NHLBI NIH HHS U10 HL069249NHLBI NIH HHS U10 HL069278NHLBI NIH HHS U10 HL069290NHLBI NIH HHS U10 HL069294NHLBI NIH HHS U10 HL069315NHLBI NIH HHS U10 HL109137NHLBI NIH HHS UG1 HL069249NHLBI NIH HHS UG1 HL069278NHLBI NIH HHS UG1 HL069286NHLBI NIH HHS UG1 HL069315
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Hematopoietic Stem Cell TransplantationHumansImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsMultiple MyelomaPrognosisSurvival AnalysisTransplantation, AutologousTransplantation, HomologousTreatment OutcomeImmunoglobulin Heavy ChainsImmunoglobulin Light Chainsfreelitehevylitemyeloma

Identifiers

PMID27292583
PMCPMC5154782

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.